Details for Patent: 8,129,362

Which drugs does patent 8,129,362 protect, and when does it expire?

Patent 8,129,362 protects EPIDUO and is included in one NDA.

This patent has thirty-five patent family members in twenty-two countries.

Summary for Patent: 8,129,362

Title:	Combination/association of adapalene and benzoyl peroxide for treating acne lesions
Abstract:	Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).
Inventor(s):	Marie-Line Abou Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
Assignee:	Galderma Research and Development SNC
Application Number:	US11/826,364
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,129,362
Patent Claim Types: see list of patent claims	Use; Compound;

US Patent 8,129,362: Scope, Claim Construction, Expiration and Epiduo Patent Landscape

US Patent 8,129,362 covers a once-daily, 12-week acne-treatment regimen using a fixed-dose combination of 0.1% adapalene and 2.5% benzoyl peroxide in a single formulation. Its claims are method-of-treatment claims, not broad composition claims. The principal commercial product associated with the claimed regimen is Galderma's Epiduo gel.

The patent's commercial importance depends on whether a competing product practices every material limitation: the two specified actives, the stated concentrations, a single fixed-dose formulation, once-daily application, and the claimed clinical or early-onset results. The patent does not broadly cover all adapalene and benzoyl peroxide products, all acne treatments, or separate sequential use of the two actives.

What drug and product does US Patent 8,129,362 protect?

US Patent 8,129,362 protects treatment regimens corresponding to Epiduo, a prescription topical gel containing:

Product	Active ingredients	FDA dosage form	Sponsor
Epiduo	0.1% adapalene / 2.5% benzoyl peroxide	Topical gel	Galderma Laboratories, L.P.
Differin	0.1% adapalene	Topical gel, cream, lotion and OTC formulations	Galderma and later generic manufacturers
Epiduo Forte	0.3% adapalene / 2.5% benzoyl peroxide	Topical gel	Galderma Laboratories, L.P.

Epiduo was approved by the FDA in December 2008 under NDA 022320 for acne vulgaris in patients 9 years of age and older. The product combines a retinoid, adapalene, with the antimicrobial and keratolytic agent benzoyl peroxide [2].

The claims supplied for US Patent 8,129,362 are directed to the 0.1%/2.5% strength, not the 0.3% adapalene strength used in Epiduo Forte.

What are the core claim limitations in US Patent 8,129,362?

The independent claims impose several cumulative requirements.

Limitation	Claims affected	Scope consequence
Acne-lesion treatment	Claims 1, 3, 5, 6, 7 and 9	Product must be used therapeutically for acne lesions
Adapalene concentration	Claims 1, 3, 5, 6, 7 and 9	0.1% adapalene, or a pharmaceutically acceptable salt
Benzoyl peroxide concentration	Claims 1, 3, 5, 6, 7 and 9	2.5% benzoyl peroxide
Fixed-dose combination	All principal regimen claims	The actives must be combined at fixed doses
Single formula	All principal regimen claims	Separate products or separate application steps are outside the literal claim
Only anti-acne active ingredients	All principal regimen claims	The formulation cannot contain another anti-acne active ingredient
Once-daily administration	All principal regimen claims	Twice-daily use does not literally satisfy the stated schedule
Twelve-week treatment period	Claims 1, 3, 5, 6, 7 and 9	The regimen includes application for 12 weeks
Gel formulation	Claims 2, 4, 5, 6, 8, 10 and 12	Several claims expressly narrow the formula to a gel
Clinical performance	Claims 1, 3, 5, 6, 7 and 9	The claimed lesion reduction or success threshold must be met
Early onset of action	Claim 11	Week 1, 2 or 4 benefit must exceed the combined monotherapy benchmark

These limitations make the patent narrower than a conventional formulation patent. A competitor may avoid literal infringement by changing concentration, dosage frequency, dosage form, active-ingredient content, or the marketed treatment instructions. The practical value of the patent therefore depends heavily on how courts construe the performance limitations and on the evidence used to establish infringement.

How do claims 1 through 10 differ?

Claims 1 through 10 divide into clinical-result groups.

Claims 1 and 2: overall treatment success

Claim 1 requires the fixed combination to achieve, in a group of subjects, a success rate of at least about 20% after once-daily treatment for 12 weeks. Claim 2 narrows the formulation to a gel.

The term "success" generally requires reference to the clinical endpoint described in the patent specification and regulatory materials. It is not an unrestricted claim to any use of the combination.

Claims 3 and 4: total lesion reduction

Claim 3 requires at least a 40% reduction in total acne lesions. Claim 4 adds the gel limitation.

This claim category captures both inflammatory and non-inflammatory lesions. A product may satisfy the concentration and dosing elements but fall outside the claim if the asserted clinical evidence does not establish the specified result.

Claim 5: non-inflammatory lesion reduction

Claim 5 requires at least a 40% reduction in non-inflammatory lesions and expressly requires a gel.

This limitation is relevant to comedonal acne outcomes. It is narrower than a general acne-treatment claim because the performance requirement is tied to a specific lesion category.

Claims 6 through 8: inflammatory lesion reduction

Claim 6 requires at least a 50% reduction in inflammatory lesions and requires a gel. Claim 7 requires at least a 40% reduction in inflammatory lesions, while claim 8 narrows claim 7 to a gel.

Claim 6 is numerically more demanding than claim 7. The two claims nevertheless differ in legal scope because each contains a separate performance threshold.

Claims 9 and 10: combined efficacy profile

Claim 9 requires all of the following:

• At least 40% reduction in total lesions.
• At least 40% reduction in non-inflammatory lesions.
• At least 40% reduction in inflammatory lesions.
• At least approximately 20% clinical success.
• Once-daily treatment for 12 weeks.
• A single formula containing only adapalene and benzoyl peroxide as anti-acne actives.

Claim 10 adds the gel limitation. Claim 9 is a cumulative claim. Failure to establish any one of the required outcomes can defeat infringement of the claim.

What does claim 11 protect?

Claim 11 is an early-onset-of-action claim. It covers once-daily use of the 0.1% adapalene/2.5% benzoyl peroxide fixed combination when the combination produces a net clinical benefit at week 1, week 2, or week 4 that is numerically superior to the sum of the benefits achieved by 0.1% adapalene alone and 2.5% benzoyl peroxide alone at the corresponding time point.

The claim has four important features:

1. It does not require a specific lesion-reduction percentage.
2. It requires comparison against each monotherapy.
3. The comparison uses the sum of the monotherapy benefits.
4. The benefit must occur at an early time point, rather than only at week 12.

The phrase "at least one of week 1, week 2 and week 4" permits infringement based on one qualifying early time point. A clinical program showing superiority only at week 12 would not satisfy the express early-onset limitation.

Claim 12 purports to depend on claim 10, although the supplied claim language identifies it as a regimen for early onset and then refers to claim 10. That apparent dependency inconsistency should be checked against the issued patent and prosecution history. Dependency defects can affect claim construction, correction, and enforceability analysis.

Is US Patent 8,129,362 a formulation patent or a method-of-use patent?

US Patent 8,129,362 is principally a method-of-treatment patent.

It does not claim:

• A composition defined solely by ingredients and concentrations.
• A particular gel vehicle.
• A specific polymer, emulsifier, solvent or stabilizer.
• A manufacturing process.
• A package, applicator or delivery system.
• Adapalene or benzoyl peroxide individually.
• All fixed combinations of adapalene and benzoyl peroxide.

Claims 2, 4, 5, 6, 8, 10 and 12 include a gel limitation, but the gel requirement appears as part of the treatment regimen. A generic manufacturer could still face infringement exposure if it sells a 0.1%/2.5% gel with labeling that instructs the claimed use, even if the vehicle differs from Epiduo's vehicle.

A different gel vehicle may avoid a separate composition patent but not necessarily avoid a method claim. Conversely, a product containing the same active ingredients could avoid these claims if it is not labeled or used according to the claimed regimen, subject to induced-infringement and contributory-infringement principles.

When does US Patent 8,129,362 lose exclusivity?

The reported US patent term for US 8,129,362 extends into 2027, with the FDA Orange Book historically identifying a June 2027 expiration date for the listed patent [1]. The precise enforceability analysis should account for any patent-term adjustment, terminal disclaimer, maintenance-fee status and statutory extensions reflected in the USPTO and FDA records.

Milestone	Date or status
Patent	US 8,129,362
Grant date	March 6, 2012
FDA product association	Epiduo, NDA 022320
FDA approval of Epiduo	December 2008
Reported Orange Book expiration	June 2027
Patent category	Method of treatment
Product strength	0.1% adapalene / 2.5% benzoyl peroxide
Exclusivity type	Small-molecule drug patent, not biologic exclusivity

Patent expiration does not eliminate every possible barrier to competition. Other patents, regulatory exclusivity, formulation rights, trade secrets, trademarks, state-law claims and manufacturing know-how may remain relevant. For Epiduo, however, this patent is the central US method patent associated with the fixed-dose 0.1%/2.5% product.

What is the Orange Book status of Epiduo?

Epiduo was listed in the FDA Orange Book with US Patent 8,129,362 as a patent relevant to the approved product [1]. The listing is significant for ANDA applicants because a generic applicant must make a patent certification under Hatch-Waxman.

The likely certification pathways are:

Certification	Meaning for a generic applicant
Paragraph I	No patent information is listed
Paragraph II	Listed patent has expired
Paragraph III	Applicant will wait until patent expiration
Paragraph IV	Patent is invalid, unenforceable or will not be infringed

A Paragraph IV filing can trigger patent litigation if the brand holder sues within the statutory period. A successful Paragraph IV challenge may permit earlier launch. A Paragraph III certification delays approval until the listed patent expires.

Because US 8,129,362 contains method-of-use claims, an applicant could pursue a section viii statement and omit the patented indication or dosing instructions if the FDA-approved labeling permits a commercially viable carve-out. Whether a carve-out is effective depends on the exact approved indication, labeling language and the claims listed for the reference product.

Which companies challenge or compete with Epiduo?

Competition comes from three groups:

Generic fixed-dose combinations

Generic manufacturers may seek approval for adapalene/benzoyl peroxide gel at the same 0.1%/2.5% strength. These products are the most direct commercial substitutes for Epiduo and present the highest relevance to US 8,129,362.

A same-strength generic that carries once-daily acne-treatment labeling creates a stronger method-patent risk than a product with a different concentration or labeling strategy.

Single-agent adapalene products

Differin and generic adapalene products compete with Epiduo but do not necessarily practice the fixed-dose combination claims. They may be used sequentially with benzoyl peroxide, but separate use does not literally satisfy the "single formula" limitation.

Alternative acne combinations

Other topical combinations include clindamycin/benzoyl peroxide, tretinoin/benzoyl peroxide and other retinoid-antimicrobial products. These products generally do not fall within the claims because adapalene and benzoyl peroxide must be the only anti-acne active ingredients in the claimed formula.

What generic launch risks exist?

The principal generic-launch scenarios are as follows.

Scenario	Patent exposure	Commercial effect
Same 0.1%/2.5% gel, once daily	High, if patent remains enforceable	Direct Epiduo substitution
Same actives in a cream or lotion	Lower under gel claims, but claims 1, 3, 7 and 9 remain relevant	Potential non-gel pathway
Separate adapalene and benzoyl peroxide products	Lower literal risk	Less convenient substitute
Different adapalene concentration	Generally outside the claims	Epiduo Forte or other strength strategy
Same product with carved-out labeling	Depends on FDA-approved indication and label	May reduce induced-infringement risk
Launch after listed patent expiration	No infringement of an expired patent	Conventional generic entry

The most material claim risk is not merely the formulation composition. It is the combination of product design and labeling. A generic product with the same strength, same dosage form and once-daily acne instructions is more exposed than a product marketed for a different regimen.

How strong is the patent estate for Epiduo?

US 8,129,362 has meaningful historical coverage but limited breadth.

Strengths

• It maps closely to the commercial Epiduo strength.
• It covers a fixed-dose, single-formula product rather than only separate coadministration.
• It includes clinical efficacy limitations that correspond to the product's development program.
• Claim 11 adds a distinct early-onset theory of protection.
• Several claims cover a gel, the principal marketed dosage form.

Weaknesses

• The claims are method claims and require proof of the claimed treatment regimen.
• The fixed concentrations narrow design-around options but also make the claims product-specific.
• The "synergistically" and clinical-performance language may create claim-construction and proof issues.
• The "only anti-acne active ingredients" limitation excludes formulations with additional acne actives.
• Once-daily and 12-week requirements may complicate induced-infringement allegations if generic labeling is carved out.
• The reported 2027 expiration materially limits remaining term value.

The patent is stronger against an identical labeled copy of Epiduo than against alternative adapalene/benzoyl peroxide products, separate products or different strengths.

Are biosimilar issues relevant to Epiduo?

No. Epiduo is a small-molecule topical drug, not a biologic. Biosimilar approval under section 351(k) of the Public Health Service Act is not the relevant pathway. Competition proceeds primarily through ANDAs under section 505(j) of the Federal Food, Drug, and Cosmetic Act, with Orange Book patent certifications under Hatch-Waxman [2, 3].

The relevant regulatory barriers are bioequivalence, quality, formulation sameness or permissible differences, labeling, manufacturing controls and patent certification. Biosimilar interchangeability standards do not apply.

What manufacturing and IP barriers remain after patent expiration?

The patent does not disclose a broad manufacturing monopoly over adapalene or benzoyl peroxide. Those ingredients are established small molecules. The principal technical barriers are:

• Maintaining benzoyl peroxide stability in the presence of adapalene.
• Controlling oxidation and degradation products.
• Achieving uniform active distribution in the gel.
• Matching rheology, spreadability and drying characteristics.
• Demonstrating microbiological quality and preservative performance.
• Establishing product sameness or acceptable differences for ANDA approval.
• Producing commercial-scale batches with consistent assay and impurity profiles.

These barriers can affect development cost and launch timing, but they do not extend the statutory patent term. Trade secrets relating to vehicle processing, filling and stability may remain commercially relevant if they are not readily ascertainable from the marketed product.

What litigation and settlement issues affect US 8,129,362?

A Paragraph IV challenge to a listed Epiduo patent can result in an infringement action under 35 U.S.C. §271(e)(2). The key litigation questions would include:

1. Whether the proposed generic's labeling directs once-daily treatment.
2. Whether the product is a single fixed-dose formula.
3. Whether the product contains only adapalene and benzoyl peroxide as anti-acne actives.
4. Whether the clinical-result limitations are inherent, intended-use limitations or enforceable performance limitations.
5. Whether "synergistically" has a measurable technical meaning.
6. Whether the generic's proposed label supports induced infringement.
7. Whether any claim is invalid for anticipation, obviousness, written-description deficiency or indefiniteness.

Settlement agreements between a brand company and an ANDA applicant may provide a license date, an authorized-generic arrangement or other market-entry terms. Such agreements must be assessed against the FTC's pharmaceutical settlement framework and any filed district-court consent judgment [4]. Patent expiry and FDA approval status remain separate issues: settlement can permit launch before expiry, while FDA approval alone does not eliminate patent liability.

Key Takeaways

• US Patent 8,129,362 is a method-of-treatment patent associated with Epiduo.
• Its central subject is once-daily use for 12 weeks of a single formula containing 0.1% adapalene and 2.5% benzoyl peroxide.
• The claims require the two actives to be the only anti-acne active ingredients.
• Claims 3 through 10 require specified lesion-reduction outcomes.
• Claim 11 targets early clinical benefit at week 1, 2 or 4 compared with the additive benefits of monotherapy.
• The patent does not broadly claim every adapalene/benzoyl peroxide composition.
• Gel claims are narrower than the non-gel regimen claims.
• Epiduo is regulated as a small-molecule drug through the NDA/ANDA and Orange Book framework, not the biosimilar pathway.
• The reported Orange Book patent expiration is June 2027.
• The highest generic risk is an identical 0.1%/2.5% gel with once-daily acne-treatment labeling.
• Separate products, different strengths, alternative dosage forms and carved-out labeling may reduce literal infringement exposure.

FAQs About US Patent 8,129,362

Does US Patent 8,129,362 cover generic adapalene alone?

No. The claims require adapalene and benzoyl peroxide together in a fixed-dose single formula. Adapalene-only products are outside the literal scope.

Does applying Differin and benzoyl peroxide separately infringe the patent?

Not literally under the supplied claims because the actives must be combined in a single formula. Induced or contributory infringement would require a separate analysis based on product instructions and conduct.

Does Epiduo Forte fall within US Patent 8,129,362?

Generally no, because Epiduo Forte contains 0.3% adapalene rather than the claimed 0.1% concentration. Separate patent rights may apply to the 0.3% product.

Can a generic avoid the patent by using a cream instead of a gel?

Claims that expressly require a gel may be avoided by a cream, but claims without the gel limitation must still be analyzed. Dosage form alone does not eliminate all exposure.

Is the 12-week period a mandatory infringement requirement?

For the claims supplied, yes. The asserted regimen must include once-daily application for 12 weeks. The clinical evidence and proposed labeling would determine whether that limitation is practiced.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
2. U.S. Food and Drug Administration. (2008). Epiduo (adapalene and benzoyl peroxide) gel, 0.1%/2.5%: Prescribing information. FDA.
3. U.S. Food and Drug Administration. (2017). Abbreviated new drug application approvals and patent certification requirements. FDA.
4. Federal Trade Commission. (2013). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. FTC.
5. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,129,362: Methods of treating acne with adapalene and benzoyl peroxide. USPTO.

Drugs Protected by US Patent 8,129,362

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008		DISCN	Yes	No						TREATMENT OF ACNE

Foreign Priority and PCT Information for Patent: 8,129,362

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	06 52968	Jul 13, 2006

International Family Members for US Patent 8,129,362

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061989
Australia	2007274288
Brazil	PI0713182
Canada	2656456
China	101541320